about
Novel anticancer targets and drug discovery in post genomic age.Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.Soluble Guanylate Cyclase: a New Therapeutic Target for Fibrotic Diseases.Design, synthesis and anti-fibrosis activity study of N₁-substituted phenylhydroquinolinone derivatives.Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitorsNovel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. IIDual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivativesBinding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors
P50
Q36048302-4C6A4E32-02F6-46E1-B5C3-B7C950560EEFQ38275441-F8314987-16F9-49DF-94FD-80F24551404FQ38397326-C64DEBC6-B650-4B2A-925D-C32F446994DFQ38705968-52B33E67-CB41-490A-B4F9-8627C1F0C4A3Q39293991-D4483D2B-5345-40D2-BAAF-283D61447CF4Q39402319-9CD28B52-014A-444B-90E4-ADEB83FA3F91Q39420876-0BCB73C3-624A-4F8C-A859-3CC4785268B2Q39444900-AFBA4014-4608-4E2B-900B-7DF4590D8DA9Q39688093-0C08E41F-0526-4F24-80D4-06BFA769F0C8Q39792692-CFED0828-C0AF-4A1F-9654-62C9CCAF293CQ43291262-143D79AA-07A4-42A3-88AD-E2604A753195Q49723404-C39558C2-A9A8-470E-8E76-25A8036850D9Q80157253-D846E2E2-1C53-4AAE-B262-5B964323428DQ82771496-D483C035-943B-4ED9-B6B4-12E523BD9424Q91687442-1313B89C-90A8-4A7E-9BA2-1A46486F2BB9Q92705489-9460CFD2-A3D0-423A-A967-4C911CD7871D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Qianbin Li
@en
Qianbin Li
@nl
type
label
Qianbin Li
@en
Qianbin Li
@nl
prefLabel
Qianbin Li
@en
Qianbin Li
@nl
P108
P31
P496
0000-0003-4522-3067